1001409-50-2 Usage
Uses
Used in Pharmaceutical Industry:
PDK1 inhibitor is used as a therapeutic agent for the treatment of cancer, as it can disrupt cancer cell proliferation by inhibiting the activity of PDK1, a key regulator of cell growth and survival.
PDK1 inhibitor is also used as a therapeutic agent for the treatment of diabetes, as it can enhance insulin sensitivity by blocking the activity of PDK1, which is involved in the regulation of cellular metabolism.
Additionally, PDK1 inhibitors are used in the research and development of drugs targeting other diseases, as they can modulate various signaling pathways involved in disease progression by inhibiting PDK1 activity. Ongoing research into PDK1 inhibitors aims to explore their potential as therapeutic agents for a range of medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1001409-50-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,1,4,0 and 9 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1001409-50:
(9*1)+(8*0)+(7*0)+(6*1)+(5*4)+(4*0)+(3*9)+(2*5)+(1*0)=72
72 % 10 = 2
So 1001409-50-2 is a valid CAS Registry Number.
1001409-50-2Relevant academic research and scientific papers
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery
Erlanson, Daniel A.,Arndt, Joseph W.,Cancilla, Mark T.,Cao, Kathy,Elling, Robert A.,English, Nicki,Friedman, Jessica,Hansen, Stig K.,Hession, Cathy,Joseph, Ingrid,Kumaravel, Gnanasambandam,Lee, Wen-Cherng,Lind, Ken E.,McDowell, Robert S.,Miatkowski, Konrad,Nguyen, Christine,Nguyen, Thinh B.,Park, Sophia,Pathan, Nuzhat,Penny, David M.,Romanowski, Michael J.,Scott, Daniel,Silvian, Laura,Simmons, Robert L.,Tangonan, Bradley T.,Yang, Wenjin,Sun, Lihong
, p. 3078 - 3083 (2011/06/26)
We report the use of a fragment-based lead discovery method, Tethering with extenders, to discover a pyridinone fragment that binds in an adaptive site of the protein PDK1. With subsequent medicinal chemistry, this led to the discovery of a potent and hig
PYRIDINONYL PDK1 INHIBITORS
-
Page/Page column 100, (2008/06/13)
The present invention provides pyridinonyl PDKl inhibitors and methods of treating cancer using the same.
